EyePoint Pharmaceuticals (EYPT) May Report Negative Earnings: Know the Trend Ahead of Q2 ReleaseZacks Investment Research • 07/28/21
EyePoint Pharmaceuticals to Report Second Quarter 2021 Financial Results on August 4, 2021GlobeNewsWire • 07/28/21
EyePoint Pharmaceuticals Receives Preliminary Extension to Pass-Through Payment Status for DEXYCU®GlobeNewsWire • 07/20/21
EyePoint Pharmaceuticals Announces New Category III CPT Code for DEXYCU® Intraocular Suspension, Approved by the American Medical AssociationGlobeNewsWire • 07/01/21
EyePoint Pharmaceuticals to Participate in Fireside Chat at the Jefferies Virtual Healthcare ConferenceGlobeNewsWire • 05/26/21
EyePoint Pharmaceuticals Announces Completion of Enrollment of Phase 1 DAVIO Clinical Trial of EYP-1901 for the Potential Treatment of Wet AMDGlobeNewsWire • 05/25/21
EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2021 Results - Earnings Call TranscriptSeeking Alpha • 05/05/21
EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Misses Revenue EstimatesZacks Investment Research • 05/05/21
EyePoint Pharmaceuticals Reports First Quarter 2021 Financial Results and Highlights Recent Corporate DevelopmentsGlobeNewsWire • 05/05/21
Will EyePoint Pharmaceuticals (EYPT) Report Negative Q1 Earnings? What You Should KnowZacks Investment Research • 04/28/21
EyePoint Pharmaceuticals to Report First Quarter 2021 Financial Results and Discuss Recent Corporate Developments on May 5, 2021GlobeNewsWire • 04/28/21
EyePoint Pharmaceuticals' (EYPT) CEO Nancy Lurker on Q4 2020 Results - Earnings Call TranscriptSeeking Alpha • 03/04/21
EyePoint Pharmaceuticals (EYPT) Reports Q4 Loss, Lags Revenue EstimatesZacks Investment Research • 03/04/21
EyePoint Pharmaceuticals to Report Fourth Quarter and Full Year 2020 Financial Results on March 4, 2021GlobeNewsWire • 02/25/21
EyePoint Pharmaceuticals Announces Closing of $115 Million Public Offering of Common StockGlobeNewsWire • 02/04/21
EyePoint Pharmaceuticals Announces First Patient Dosed in Phase 1 Clinical Trial of EYP-1901 for the Treatment of Wet AMDGlobeNewsWire • 01/28/21
EyePoint Pharmaceuticals Provides Business Update and Preliminary Fourth Quarter and Full-Year 2020 Net Product RevenuesGlobeNewsWire • 01/11/21
Week In Review: China Biopharma Starts 2021 With Over $1 Billion In Deals And IPOsSeeking Alpha • 01/10/21
EyePoint Pharmaceuticals Announces $15.7 Million Equity Investment by Asia Partner Ocumension TherapeuticsGlobeNewsWire • 01/04/21
EyePoint Pharmaceuticals Announces $16.5 Million Monetization of ILUVIEN® Royalty with SWK Holdings CorporationGlobeNewsWire • 12/18/20